PTH and hypercalcemia disease: Regarding PTH analogs, one of the studies included in this analysis indicated that treatment with only teriparatide at 40 μg/day in patients with mild CKD resulted in a significant improvement in eGFR, whereas other interventions had no substantial effect and may lead to adverse events, such as hypercalcemia and hyperuricemia (Miller et al., 2007).